Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.
Arsenault, Daniel
Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy. [electronic resource] - American journal of clinical oncology Aug 2015 - 348-52 p. digital
Publication Type: Journal Article
1537-453X
10.1097/COC.0b013e31829d1eb8 doi
Adult
Aged
Antibodies, Monoclonal, Humanized--therapeutic use
Antineoplastic Agents--therapeutic use
Breast Neoplasms--drug therapy
Carcinoma, Ductal, Breast--drug therapy
Chemotherapy, Adjuvant
Cohort Studies
Female
Humans
Lymph Nodes--pathology
Mastectomy
Mastectomy, Segmental
Middle Aged
Neoadjuvant Therapy
Neoplasm Recurrence, Local
Neoplasm Staging
Neoplasm, Residual
Radiotherapy, Adjuvant
Receptor, ErbB-2--metabolism
Receptors, Estrogen--metabolism
Retrospective Studies
Risk Factors
Trastuzumab
Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy. [electronic resource] - American journal of clinical oncology Aug 2015 - 348-52 p. digital
Publication Type: Journal Article
1537-453X
10.1097/COC.0b013e31829d1eb8 doi
Adult
Aged
Antibodies, Monoclonal, Humanized--therapeutic use
Antineoplastic Agents--therapeutic use
Breast Neoplasms--drug therapy
Carcinoma, Ductal, Breast--drug therapy
Chemotherapy, Adjuvant
Cohort Studies
Female
Humans
Lymph Nodes--pathology
Mastectomy
Mastectomy, Segmental
Middle Aged
Neoadjuvant Therapy
Neoplasm Recurrence, Local
Neoplasm Staging
Neoplasm, Residual
Radiotherapy, Adjuvant
Receptor, ErbB-2--metabolism
Receptors, Estrogen--metabolism
Retrospective Studies
Risk Factors
Trastuzumab